Modern Medicine Feature Articles

Ziv-aflibercept for DME provides BCVA gains, lower dosing burdenResults of a 1-year randomized controlled trial investigating treatment for diabetic macular edema (DME) show that intravitreal ziv-aflibercept (Zaltrap, Sanofi Genzyme) 1.25 or 2.5 mg is safe, according to Masoud Soheilian, MD.
PCa active surveillance trends revealed in ‘real-world’ studyNearly three-fourths of men with very low-risk prostate cancer underwent active surveillance as a primary therapy, according to a study presented at the LUGPA annual meeting in Chicago.
Prevent burnout by restoring professional fulfillment“The answer is to remove the barriers and frustrations that are causing burnout so that physicians can focus on their role as care providers,” advises Paul DeChant, MD, MBA.
How care process models can help your practice“Care process models… represent a way to decrease variation and waste, and thereby they lead to improved outcomes and significant cost reductions,” says Jay T. Bishoff, MD.
Urology-specific APMs to encompass PCa, BPH, OAB“The APMs being designed by LUGPA allow for participation by all urologists regardless of their practice setting or affiliation,” explains Alec Koo, MD.
NLP status after open-globe injury not always permanentManagement of patients with loss of light perception after open-globe injury has historically been to observe or enucleate the eye with the goal of reducing the risk of sympathetic ophthalmia. Existing data, however, support rethinking that paradigm and instead considering surgery for carefully selected patients who have a chance for recovering vision.
Add-on injectable IOL for pseudophakic AMD maintains near visionResults from 1 year of follow-up in a multicenter clinical trial show that an add-on (Scharioth Macula Lens [SML], Medicontour) increases near vision without affecting distance vision in pseudophakic patients with age-related macular degeneration (AMD).
Punctal plug drug delivery attractive method for managing glaucomaPunctal plug-based delivery systems for sustained delivery of glaucoma medications represent new and versatile technology that is under development. The hope is it can help with the problem of patient compliance when managing mild-moderate glaucoma, said Marlene Moster, MD.
Tumor-targeted therapy changing game for choroidal melanomaEarly results of a phase Ib/II study investigating light-activated AU-011 (Aura Biosciences) for treatment of small-medium choroidal melanoma show good safety and evidence of efficacy for this novel tumor-targeted therapy.
Finding alternative techniques for eyes with failed PKCornea surgeons encountering a patient with failed penetrating keratoplasty (PK) will wonder if they should repeat the PK. Although there are some exceptions to the rule, according to Donald T.H. Tan, MD, the answer is “no.”